transitioning patients off CLEVIPREX® (clevidipine)

Learn about CLEVIPREX® (clevidipine)

Considerations when transitioning to oral antihypertensive therapy

Considerations when no oral antihypertensive therapy has been initiated1

  • Consider differences in pharmacokinetics and pharmacodynamics between CLEVIPREX and oral therapy1
    • Oral therapy will have a lag time of onset
    • Half-life of CLEVIPREX is ~1 minute; full recovery of BP occurs 5–15 minutes after discontinuation in most patients
  • Discontinue CLEVIPREX or down titrate as oral therapy takes effect1
  • Continue BP monitoring until desired BP is achieved1
  • In a study in acute severe hypertension, oral therapy was started prior to discontinuation or down titration of CLEVIPREX2
  • In most patients, full recovery of BP occurs 5–15 minutes after CLEVIPREX infusion is stopped
  • Monitor for rebound hypertension for at least 8 hours after CLEVIPREX infusion is stopped
  • Follow-up adjustments in BP control may be needed

Other dosing guidelines

There are additional storage, handling, and administration guidelines to consider when using CLEVIPREX.

50 mL and 100 mL CLEVIPREX single-use vials

Individualized, titratable administration1

CLEVIPREX has a low-volume, non–weight-based dosing regimen that is independent of renal or hepatic function.1

Demonstrated safety profile

The safety profile of CLEVIPREX was evaluated in multiple clinical trials.1